Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

14.38 -0.35 (-2.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT... 
Via Benzinga
NASDAQ:ACAD Investor Notice: Lawsuit Alleges Misleading Statements by ACADIA Pharmaceuticals Inc
San Diego, CA -- (SBWIRE) -- 05/04/2021 -- An investor, who purchased NASDAQ:ACAD shares, filed a lawsuit against ACADIA Pharmaceuticals Inc over alleged Securities Laws violations. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
SHAREHOLDER ALERT: Law Offices of Timothy L. Miles Is Investigating Acadia Pharmaceuticals Inc. on Behalf of Investors
SHAREHOLDER ALERT: The Law Offices of Timothy L. Miles Is Investigating Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Shareholders 
Via EIN Presswire
Topics Lawsuit
Exposures Financial Legal Product Safety
Cramer Gives His Opinion On Lemonade, Pinterest And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he still likes Lemonade Inc (NYSE: LMND). Investors will have to wait a long time for the value of the stock... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
From Glancy Prongay & Murray LLP
Via Business Wire
ACAD Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds ACADIA Pharmaceuticals Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)
From Law Offices of Howard G. Smith
Via Business Wire
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Acadia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline – ACAD
From Rosen Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Shareholder Alert: Robbins LLP Is Investigating Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors
From Law Offices of Howard G. Smith
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Acadia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock rose 5.26% to $1.2 during Tuesday's after-market session. This security traded at a volume of 43.6K shares come close, making up... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET on Monday, 30 stocks hit new 52-week lows. Interesting Highlights: The largest company by market cap to set a new 52-week low was Ionis Pharmaceuticals (... 
Via Benzinga
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 13 companies achieved new lows for the year. Intriguing Points: The largest company by market cap to set a new 52-week low was Cia Paranaense De... 
Via Benzinga
Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over
Regulatory and drug-pricing worries have knocked biotech stocks off their pedestal. After hitting a high point in February, biotech stocks have fallen 20%. 
Via Investor's Business Daily
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2021
Upgrades According to Janney Capital, the prior rating for Texas Capital Bancshares Inc (NASDAQ:TCBI) was changed from Neutral to Buy. Texas Capital Bancshares earned $1.... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.